Lincoln Pharmaceuticals's quarterly market cap
declined
from Sep. 2025 (₹10,660 Mil) to Dec. 2025 (₹9,694 Mil) but then
increased
from Dec. 2025 (₹9,694 Mil) to Mar. 2026 (₹11,316 Mil).
Lincoln Pharmaceuticals's annual market cap
declined
from Mar. 2024 (₹11,739 Mil) to Mar. 2025 (₹11,047 Mil) but then
increased
from Mar. 2025 (₹11,047 Mil) to Mar. 2026 (₹11,316 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Lincoln Pharmaceuticals's Enterprise Value for Today is ₹10,044 Mil.
Lincoln Pharmaceuticals (NSE:LINCOLN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Lincoln Pharmaceuticals Market Cap Related Terms
Lincoln Pharmaceuticals Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lincoln Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lincoln Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lincoln Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Lincoln Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Lincoln Pharmaceuticals's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lincoln Pharmaceuticals (NSE:LINCOLN) has a Market Cap of ₹12,419 Mil as of Jul. 06, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lincoln Pharmaceuticals and its competitors. According to the industry distribution chart, Lincoln Pharmaceuticals ranks #577 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 56.5%.
Is Lincoln Pharmaceuticals' Market Cap too high?
Lincoln Pharmaceuticals' current Market Cap is ₹12,419 Mil. Based on the distribution chart, Lincoln Pharmaceuticals ranks #577 out of 1022 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Lincoln Pharmaceuticals has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lincoln Pharmaceuticals' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Lincoln Pharmaceuticals ranks #577 out of 1022 companies for Market Cap. This places Lincoln Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 221.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 221.60, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lincoln Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 221.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lincoln Pharmaceuticals's current Market Cap is ₹12,419 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lincoln Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals (NSE:LINCOLN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹704.02, compared to a current price of ₹620.20 — trading 11.9% below its estimated fair value. The current Market Cap is ₹12,419 Mil. Lincoln Pharmaceuticals' overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Lincoln Pharmaceuticals (NSE:LINCOLN), the current Market Cap is ₹12,419 Mil as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lincoln Pharmaceuticals (NSE:LINCOLN) Overvalued in 2026?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹620.20 is trading 11.9% below its estimated GF Value™ of ₹704.02.
GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:LINCOLN:
Market Cap: ₹12,419 Mil
GF Value™: ₹704.02 vs. price of ₹620.20 (11.9% below fair value)
No single metric tells the full story. See the NSE:LINCOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
85GF Score
Get the complete analysis for NSE:LINCOLN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LINCOLN has been successfully added to your 
